GH Research (GHRS) Competitors

Apellis Pharmaceuticals (NASDAQ:APLS) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.

Does the MarketBeat Community favor APLS or GHRS?

Apellis Pharmaceuticals received 318 more outperform votes than GH Research when rated by MarketBeat users. However, 77.27% of users gave GH Research an outperform vote while only 66.29% of users gave Apellis Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Apellis Pharmaceuticals	Outperform Votes 352 66.29%	Underperform Votes 179 33.71%
GH Research	Outperform Votes 34 77.27%	Underperform Votes 10 22.73%

Which has stronger earnings and valuation, APLS or GHRS?

GH Research has lower revenue, but higher earnings than Apellis Pharmaceuticals. GH Research is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apellis Pharmaceuticals	$775.84M	3.04	-$528.63M	-$1.79	-10.50
GH Research	N/A	N/A	-$35.59M	-$0.79	-17.68

Is APLS or GHRS more profitable?

GH Research has a net margin of 0.00% compared to Apellis Pharmaceuticals' net margin of -34.97%. GH Research's return on equity of -20.29% beat Apellis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apellis Pharmaceuticals	-34.97%	-103.11%	-28.96%
GH Research	N/A	-20.29%	-19.49%

Does the media prefer APLS or GHRS?

In the previous week, Apellis Pharmaceuticals had 3 more articles in the media than GH Research. MarketBeat recorded 13 mentions for Apellis Pharmaceuticals and 10 mentions for GH Research. Apellis Pharmaceuticals' average media sentiment score of 1.10 beat GH Research's score of 0.98 indicating that Apellis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apellis Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GH Research	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate APLS or GHRS?

Apellis Pharmaceuticals presently has a consensus target price of $40.05, indicating a potential upside of 113.16%. GH Research has a consensus target price of $32.00, indicating a potential upside of 129.06%. Given GH Research's stronger consensus rating and higher possible upside, analysts plainly believe GH Research is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apellis Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.62
GH Research	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, APLS or GHRS?

Apellis Pharmaceuticals has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, GH Research has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in APLS or GHRS?

96.3% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 6.5% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 41.6% of GH Research shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

GH Research beats Apellis Pharmaceuticals on 10 of the 18 factors compared between the two stocks.